Fibromyalgia Impact Questionnaire (FIQ)

Bennett R; Burckhardt C; Clark S

Distributed by Mapi Research Trust

Distributed by Mapi Research Trust

default distrib

Basic description

Developed in 1989, first published in 1991 (v1.0) and modified in 1997 (v2.0) and 2002
A revised version was developed in 2009: the Revised Fibromyalgia Impact Questionnaire (FIQR) which since superseded the FIQ

The original 1991 FIQ was modified in 1997, when 1 item (climb stairs) was added to the physical function subscale, hashmarks were added to the visual analogue scales to make scoring easier, and the words "including housework" were added to the 2 work-related items so that housework was recognized as a legitimate type of work. To avoid any confusion between both versions, each version has been numbered as follows:

  • FIQ 1991 will be version 1.0.
  • FIQ 1997 revised will be version 2.0.
  • FIQ 2.1 is the current version available

Bennett R; Burckhardt C; Clark S

FIQ © Drs Burckhardt CS, Clark SR, Bennett RM 1991, All rights reserved.
To measure fibromyalgia patient status, progress and outcomes
Therapeutic area
  • Nervous System Diseases
  • Musculoskeletal Diseases
Therapeutic indication


Type of Clinical Outcome Assessment (COA)
Original language(s)
  • English for the USA
Bibliographic reference(s) of the original questionnaire

Burckhardt CS, Clark SR, Bennett RM. The fibromyalgia impact questionnaire: development and validation. J Rheumatol. 1991 May;18(5):728-33 (PubMed abstract)

Bennett R. The Fibromyalgia Impact Questionnaire (FIQ): a review of its development, current version, operating characteristics and uses. Clin Exp Rheumatol. 2005 Sep-Oct;23(5 Suppl 39):S154-62 (PubMed abstract)

Contact and conditions of use


Bennett R; Burckhardt C; Clark S

Robert M. Bennett
Fibromyalgia Research Unit
Oregon Health & Science University
3455 SW Veterans Rd
Portland, OR 97239
Robert Bennett Publications (PubMed)

Carol S. Burckhardt, PhD,
Carol Burckhardt Publications (PubMed)

Sharon Clark
Sharon Clark Publications (PubMed)

Contact information

Mapi Research Trust
27 rue de la Villette
69003 Lyon
Phone: +33 (0)4 72 13 66 66

Conditions of use

Non-Commercial Users

If you do not receive specific funding for your study, you may download the questionnaire directly:

  1. Log in or Register for free
  2. Click the 'Online distribution' tab in the left menu bar and follow the instructions

Tutorials are available on our FAQs.

Commercial Users

All requests have to be submitted through our online request management:

  1. Log in or Register for free
  2. Submit your request (Tutorials are available on our FAQs)
  3. In order to accelerate the process, you may attach the User Agreement (even if not finalized) to your online request. Click the link below for the user agreement template.
  4. Our PROVIDE team will get back to you with the needed information in a timely manner

Access fees

ROYALTY FEES* Commercial users Cost per study 1100 € (use in commercial epidemiologic / observational / marketing studies: please consult the user-agreement)
Cost per language 550 € (use in commercial epidemiologic / observational / marketing studies: please consult the user-agreement)
Funded academic research Cost per study Free
Cost per language Free
Not funded academic users Cost per study Free
Cost per language Free
DISTRIBUTION FEES* Commercial users Cost per study 700 €
Cost per language 300 €
Funded academic research Cost per study 300 €
Cost per language 50 €
Not funded academic users Cost per study Free
Cost per language Free

* Excluding VAT
Commercial users: Industry, CRO, any for-profit companies
Funded Academic research: Projects receiving funding from commerce, government, EU or registered charity. Funded academic research– sponsored by industry fits the “commercial users” category.
Not funded academic users, individual medical practice: Projects are not explicitly funded, but funding comes from overall departmental funds or from the University or individual funds

Author Website(s)

Additional information on the FIQ website 

Review copy

Examination copies can only be used for the limited purpose of examining the suitability of the Questionnaire for subsequent research and/or clinical use, and cannot be used in research or in clinical practice or distributed to others.
You are not authorized to modify, retype, translate, copy or otherwise duplicate the Questionnaire except with the further and prior written permission of Mapi Research Trust / the developers / copyright holders / distributors.

Online distribution

For Non-Funded Academic Studies

The following licensing process is restricted to academic users:

  • Who do not receive specific funding for their study
  • Who intend to use the questionnaire in individual clinical practice or research study

Should you not correspond to this category of users, please send us a request.

Note: This site aims at providing you with the original version and existing translations of the questionnaire. However some modules/versions may not be downloadable in the language you need.

If you are interested in specific language(s), please first consult the list of existing translations in PROQOLID.


To access this section, please complete a client account.


Original language(s)

  • English for the USA


The translations listed may not have undergone a full linguistic validation process and may require further work to be suitable for use in a study. This list is subject to constant changes, therefore please check the status of translations with Mapi Research Trust / the developers / copyright holders / distributors.


Afrikaans for South Africa*
Arabic for Israel*
Arabic for Jordan*
Bengali for India*
Bulgarian for Bulgaria*
Catalan for Spain
Croatian for Croatia*
Czech for Czech Republic*
Danish for Denmark*
Dutch for Belgium (Flemish)*
Dutch for the Netherlands*
English for Australia*
English for Canada*
English for India*
English for Ireland
English for New Zealand*
English for South Africa*
English for the UK*
Estonian for Estonia*
Filipino for the Philippines*
Finnish for Finland*
French for Belgium*
French for Canada*
French for France*
French for Switzerland*
Georgian for Georgia*
German for Austria*
German for Germany*
German for Switzerland*
Greek for Greece*
Gujarati for India*
Hebrew for Israel*
Hindi for India*
Hungarian for Hungary*
Icelandic for Iceland
Italian for Italy*
Italian for Switzerland*
Kannada for India*
Korean for Korea*
Latvian for Latvia*
Lithuanian for Lithuania*
Malayalam for India*
Mandarin for China*
Mandarin for Taiwan*
Marathi for India*
Norwegian for Norway*
Polish for Poland*
Portuguese for Brazil*
Portuguese for Portugal*
Punjabi for India*
Romanian for Romania*
Russian for Belarus*
Russian for Estonia*
Russian for Israel*
Russian for Latvia*
Russian for Lithuania*
Russian for Russia*
Russian for Ukraine*
Serbian for Serbia*
Slovak for Slovakia*
Slovenian for Slovenia*
Sotho for South Africa*
Spanish for Argentina*
Spanish for Chile*
Spanish for Colombia*
Spanish for Mexico*
Spanish for Puerto Rico*
Spanish for Spain*
Spanish for the USA*
Swedish for Finland*
Swedish for Sweden*
Tamil for India*
Telugu for India*
Turkish for Turkey*
Ukrainian for Ukraine*
Urdu for India*
Xhosa for South Africa*
Zulu for South Africa*
* Performed by Mapi

The author has selected Mapi as exclusive linguistic validation company to ensure the production of harmonized and consistent language versions.

For additional information on available translations of this instrument, or for a project involving new languages, please submit a request (tutorials available on our FAQs).

Conditions to translate

Academic Translation

If you wish to translate the questionnaire:

  1. Log in or Register for free
  2. Submit your request for translation online (Tutorials are available on our FAQs)
  3. Our PROVIDE team will send you a translation agreement along with Linguistic Validation Guidelines.

Commercial Users

Exclusive vendor for translation work for commercial users: Mapi

More information on translations

Bibliographic reference of the translations:


Poca-Dias V, Almirall-Bernabé A, Cuscó-Segarra A, García-Fructuoso FJ. Validación de la versión catalana del Fibromyalgia Impact Questionnaire. Reumatol Clin. 2006;2 (Espec Congr):63-4



Zijlstra TR, Taal E, van de Laar MA, Rasker JJ. Validation of a Dutch translation of the fibromyalgia impact questionnaire. Rheumatology (Oxford). 2007 Jan;46(1):131-4



Perrot S, Dumont D, Guillemin F, Pouchot J, Coste J, French Group for Quality of Life Research. Quality of life in women with fibromyalgia syndrome: validation of the QIF, the French version of the Fibromyalgia Impact Questionnaire. J Rheumatol. 2003;30(5):1054-1059



Offenbaecher M, Waltz M, Schoeps P. Validation of a German version of the Fibromyalgia Impact Questionnaire (FIQ-G). J Rheumatol. 2000 Aug;27(8):1984-8



Buskila D, Neumann L. Assessing functional disability and health status of women with fibromyalgia: validation of a Hebrew version of the Fibromyalgia Impact Questionnaire. J Rheumatol. 1996 May;23(5):903-6



Sarzi-Puttini P, Arzeni F, Fiorini T, Panni B, Randisi G, Turiel M, Carrabba M. Validation of an Italian version of the Fibromyalgia Impact Questionnaire (FIQ-I). Clin Exp Rheumatol. 2003; 21(4):459-464



Bae SC, Lee JH. Cross-cultural adaptation and validation of the Korean fibromyalgia impact questionnaire in women patients with fibromyalgia for clinical research. Qual Life Res 2004; 13(4):857-861

Kim YA, Lee SS, Park K. Validation of a korean version of the fibromyalgia impact questionnaire. J Korean Med Sci. 2002 Apr;17(2):220-4



Contributo para a validacao e adaptacao cultural de um instrumento de medida: "questionario de impacto da Fibromyalgia - 2A versao



Portuguese for Brazil

Pagano T, Matsutani LA, Ferreira EA, Marques AP, Pereira CA. Assessment of anxiety and quality of life in fibromyalgia patients. Sao Paulo Med J. 2004 Nov 4;122(6):252-258




Rivera J, González T. The Fibromyalgia Impact Questionnaire: a validated Spanish version to assess the health status in women with fibromyalgia. Clin Exp Rheumatol. 2004 Sep-Oct;22(5):554-60



Hedin PJ, Hamne M, Burckhardt CS, Engström-Laurent A. The Fibromyalgia Impact Questionnaire, a Swedish translation of a new tool for evaluation of the fibromyalgia patient. Scand J Rheumatol. 1995;24(2):69-75



Sarmer S, Ergin S, Yavuzer G. The validity and reliability of the Turkish version of the Fibromyalgia Impact Questionnaire. Rheumatol Int. 2000 Dec;20(1):9-12



Implemented electronically on TrialMax Touch® home-based devices


Implemented electronically on TrialMax Slate® site-based devices

Last update: October 2017
For additional information, please submit a request. More information in our FAQs.


PROLABELS symbol PROLABELS: 2 indications